**Table S1.** Counts and proportions of samples testing positive for respiratory syncytial virus (RSV) and other respiratory viruses (among all RSV-positive samples) before and during the COVID-19 pandemic, stratified by age group and setting of care. Samples were collected from January 2018 to November 2022 in Nashville, Tennessee.

|  |  |  |
| --- | --- | --- |
|  | **Before the pandemic** | **During the pandemic** |
|  | **Outpatient** | **Emergency** | **Inpatient** | **Outpatient** | **Emergency** | **Inpatient** |
| **0–4 years old, *n* (%)** | 191 | 316 | 638 | 527 | 604 | 882 |
| RSV only (*n*=1,926) | 131 (68.6%) | 183 (57.9%) | 415 (65.0%) | 278 (52.8%) | 349 (57.8%) | 570 (64.6%) |
| RSV/HRV/EV (*n*=607) | 25 (13.1%) | 53 (16.8%) | 105 (16.5%) | 132 (25.0%) | 132 (21.9%) | 160 (18.1%) |
| RSV/AdV (*n*=152) | 6 (3.1%) | 25 (7.9%) | 30 (4.7%) | 25 (4.7%) | 30 (5.0%) | 36 (4.1%) |
| RSV/HCoV (*n*=114) | 10 (5.2%) | 19 (6.0%) | 31 (4.9%) | 14 (2.7%) | 16 (2.6%) | 24 (2.7%) |
| RSV/HRV/EV/AdV (*n*=83) | 3 (1.6%) | 9 (2.8%) | 12 (1.9%) | 24 (4.6%) | 13 (2.2%) | 22 (2.5%) |
| RSV/PIV (*n*=74) | 2 (1.0%) | 3 (0.9%) | 7 (1.1%) | 18 (3.4%) | 24 (4.0%) | 20 (2.3%) |
| RSV/HRV/EV/PIV (*n*=42) | 0 (0.0%) | 0 (0.0%) | 8 (1.3%) | 13 (2.5%) | 10 (1.7%) | 11 (1.2%) |
| RSV/SARS-CoV-2 (*n*=33) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 9 (1.7%) | 10 (1.7%) | 14 (1.6%) |
| RSV/Flu (*n*=22) | 2 (1.0%) | 3 (0.9%) | 9 (1.4%) | 3 (0.6%) | 1 (0.2%) | 4 (0.5%) |
| RSV/HRV/EV/HCoV (*n*=22) | 4 (2.1%) | 6 (1.9%) | 5 (0.8%) | 0 (0.0%) | 5 (0.8%) | 2 (0.2%) |
| RSV/HMPV (*n*=16) | 1 (0.5%) | 2 (0.6%) | 6 (0.9%) | 1 (0.2%) | 4 (0.7%) | 2 (0.2%) |
| RSV/HRV/EV/SARS-CoV-2 (*n*=9) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (0.8%) | 1 (0.2%) | 4 (0.5%) |
| RSV/AdV/HCoV (*n*=7) | 1 (0.5%) | 3 (0.9%) | 3 (0.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HRV/EV/HMPV (*n*=7) | 1 (0.5%) | 2 (0.6%) | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) | 1 (0.1%) |
| RSV/PIV/AdV (*n*=6) | 1 (0.5%) | 0 (0.0%) | 1 (0.2%) | 1 (0.2%) | 2 (0.3%) | 1 (0.1%) |
| RSV/HRV/EV/AdV/SARS-CoV-2 (*n*=5) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.2%) | 1 (0.2%) | 3 (0.3%) |
| RSV/PIV/HCoV (*n*=5) | 0 (0.0%) | 1 (0.3%) | 1 (0.2%) | 0 (0.0%) | 3 (0.5%) | 0 (0.0%) |
| RSV/HRV/EV/PIV/AdV (*n*=4) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (0.4%) | 0 (0.0%) | 2 (0.2%) |
| RSV/AdV/SARS-CoV-2 (*n*=3) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (0.3%) |
| RSV/HCoV/Flu (*n*=3) | 0 (0.0%) | 2 (0.6%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HRV/EV/AdV/HCoV (*n*=3) | 1 (0.5%) | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) |
| RSV/HRV/EV/Flu (*n*=3) | 1 (0.5%) | 1 (0.3%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/AdV/HMPV (*n*=2) | 1 (0.5%) | 0 (0.0%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HRV/EV/AdV/HMPV (*n*=2) | 1 (0.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) |
| RSV/PIV/SARS-CoV-2 (*n*=2) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.2%) | 1 (0.1%) |
| RSV/AdV/Flu (*n*=1) | 0 (0.0%) | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HCoV/HMPV (*n*=1) | 0 (0.0%) | 0 (0.0%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/Flu/SARS-CoV-2 (*n*=1) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.2%) | 0 (0.0%) |
| RSV/HRV/EV/HCoV/Flu (*n*=1) | 0 (0.0%) | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HRV/EV/PIV/SARS-CoV-2 (*n*=1) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) |
| RSV/PIV/AdV/HCoV (*n*=1) | 0 (0.0%) | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| **5–17 years old, *n* (%)** | 34 | 47 | 60 | 52 | 71 | 84 |
| RSV (*n*=244) | 22 (64.7%) | 32 (68.1%) | 45 (75.0%) | 36 (69.2%) | 45 (63.4%) | 64 (76.2%) |
| RSV/HRV/EV (*n*=50) | 6 (17.6%) | 5 (10.6%) | 5 (8.3%) | 9 (17.3%) | 15 (21.1%) | 10 (11.9%) |
| RSV/AdV (*n*=10) | 1 (2.9%) | 2 (4.3%) | 2 (3.3%) | 2 (3.8%) | 0 (0.0%) | 3 (3.6%) |
| RSV/HCoV (*n*=9) | 1 (2.9%) | 4 (8.5%) | 1 (1.7%) | 0 (0.0%) | 2 (2.8%) | 1 (1.2%) |
| RSV/PIV (*n*=8) | 0 (0.0%) | 0 (0.0%) | 2 (3.3%) | 1 (1.9%) | 2 (2.8%) | 3 (3.6%) |
| RSV/HRV/EV/PIV (*n*=6) | 0 (0.0%) | 0 (0.0%) | 1 (1.7%) | 1 (1.9%) | 3 (4.2%) | 1 (1.2%) |
| RSV/Flu (*n*=5) | 1 (2.9%) | 2 (4.3%) | 2 (3.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HMPV (*n*=4) | 1 (2.9%) | 1 (2.1%) | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | 0 (0.0%) |
| RSV/HRV/EV/AdV (*n*=4) | 0 (0.0%) | 0 (0.0%) | 1 (1.7%) | 2 (3.8%) | 1 (1.4%) | 0 (0.0%) |
| RSV/PIV/HMPV (*n*=2) | 0 (0.0%) | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) |
| RSV/AdV/HMPV (*n*=1) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.2%) |
| RSV/HCoV/Flu (*n*=1) | 0 (0.0%) | 1 (2.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HCoV/HMPV (*n*=1) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) |
| RSV/HRV/EV/HCoV (*n*=1) | 1 (2.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HRV/EV/PIV/AdV (*n*=1) | 1 (2.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/SARS-CoV-2 (*n*=1) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.2%) |
| **18–64 years old, *n* (%)** | 53 | 7 | 110 | 31 | 25 | 86 |
| RSV (*n*=263) | 44 (83.0%) | 4 (57.1%) | 93 (84.5%) | 26 (83.9%) | 20 (80.0%) | 76 (88.4%) |
| RSV/HRV/EV (*n*=15) | 2 (3.8%) | 0 (0.0%) | 5 (4.5%) | 2 (6.5%) | 3 (12.0%) | 3 (3.5%) |
| RSV/HCoV (*n*=11) | 3 (5.7%) | 2 (28.6%) | 5 (4.5%) | 1 (3.2%) | 0 (0.0%) | 0 (0.0%) |
| RSV/SARS-CoV-2 (*n*=6) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (4.0%) | 5 (5.8%) |
| RSV/Flu (*n*=5) | 0 (0.0%) | 1 (14.3%) | 2 (1.8%) | 1 (3.2%) | 0 (0.0%) | 1 (1.2%) |
| RSV/HMPV (*n*=4) | 2 (3.8%) | 0 (0.0%) | 2 (1.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/AdV (*n*=3) | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 0 (0.0%) | 1 (4.0%) | 1 (1.2%) |
| RSV/HCoV/Flu (*n*=2) | 1 (1.9%) | 0 (0.0%) | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HRV/EV/HCoV (*n*=1) | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/HRV/EV/PIV (*n*=1) | 1 (1.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/PIV (*n*=1) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) | 0 (0.0%) |
| **≥65 years old, *n* (%)** | 22 | 2 | 73 | 12 | 6 | 53 |
| RSV (*n*=147) | 18 (81.8%) | 2 (100.0%) | 64 (87.7%) | 10 (83.3%) | 5 (83.3%) | 48 (90.6%) |
| RSV/HRV/EV (*n*=9) | 0 (0.0%) | 0 (0.0%) | 5 (6.8%) | 2 (16.7%) | 1 (16.7%) | 1 (1.9%) |
| RSV/HCoV (*n*=6) | 4 (18.2%) | 0 (0.0%) | 2 (2.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| RSV/SARS-CoV-2 (*n*=4) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (7.5%) |
| RSV/PIV (*n*=2) | 0 (0.0%) | 0 (0.0%) | 2 (2.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |

**Abbreviations:** RSV, respiratory syncytial virus; HRV/EV, human rhinovirus/enterovirus; HCoV, human coronaviruses; AdV, adenovirus; PIV, parainfluenza viruses 1–4; Flu, influenza A and B; HMPV, human metapneumovirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.